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Randomised clinical trials  
For MEDLINE, the MesH terms “cardiovascular disease”, “coronary heart disease”, “coronary 
stenosis”, “myocardial infarction”, “cerebrovascular accident”, “stroke”, and “randomised controlled 
trial”, “clinical trial”, and “folic acid” were utilised. We also searched for trials published only as an 
abstract in conferences or meetings1 as well as in previously published meta-analyses addressing this 
question2,3. 
For inclusion in the analysis, studies had to: (i) be randomised and parallel in design; (ii) be conducted 
in adults; (iii) examine the effects of folic acid supplementation (with or without additional vitamin B 
supplementation); (iv) record stroke as an outcome, and; (v) have 12 months minimum follow-up. 
Studies using folic acid combined with a multivitamin/mineral tablet versus placebo/standard care 
were excluded4.  
 
Genetic studies  
We used the text words, which were also MeSH terms, “polymorphism”, “mutation”, “genotype”, 
“genetic”, “gene(s)”, “allele(s)” in combination with “stroke”, “cerebrovascular disorder/disease”, 
“cerebral ischemia”, “hemorrhagic stroke”, “(silent) brain infarction”. Literature searches were limited 
to “human”. All languages were included. Additional studies in the references of all identified 
publications, including previous relevant meta-analyses were identified.  
In the analysis of the MTHFR/C677T variant on Hcy levels, studies were included if the design was 
case-control, cohort or cross-sectional. For inclusion in the analysis of MTHFR/C677T variant and 
stroke, case-control, cohort, or cross-sectional studies evaluating ischaemic, haemorrhagic or 
undifferentiated stroke were included. In all searches, when relevant information was not reported or 
there was doubt about duplicate publications, we contacted authors for clarification.  
We supplemented information from published studies with unpublished genetic data obtained through 
direct contact with investigators of any study that had previously reported at least one genetic finding 
in stroke (for case-control studies) or in cardiovascular disease (for cohorts) in a peer reviewed 
journal. This allowed us to minimise the scope for reporting and publication bias. A total of 52 
investigators of newly identified studies were asked to provided the most up-to-date information on 
the MTHFR/C677T variant and stroke risk in the form of genotype counts by disease status (cases 
[ischaemic, hemorrhagic or undifferentiated stroke] and controls) and the average values of Hcy and 
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folic acid by MTHFR/C677T genotypes in subjects without cardiovascular disease. Authors of 44 




Data extraction  
 
Randomised trials 
For randomised trials, the following variables were extracted (by MVH and JPC, see eTable 5): study 
design, patient characteristics, calendar years in which trial conducted; geographical region; type of 
stroke outcome(s) recorded; mean follow-up period, and; type of intervention(s) used as comparator 
(usual care, placebo, lower-dose folic acid, B vitamin alone). In addition, in each arm we recorded: (a) 
number of participants;  (b) number of stroke events; (c) baseline and post-intervention levels of Hcy 
(where applicable), and; (d) doses of intervention(s) used. To determine the risk of bias, we 
evaluated: (i) sequence generation; (ii) allocation concealment; (iii) incomplete outcome data, and; (iv) 
selective outcome reporting, as suggested by the Cochrane Handbook for Systematic Reviews of 
Interventions5. Disagreements were resolved by consensus. 
For each trial, point estimates of relative risk with 95% confidence intervals were derived using values 
of outcome events in each study arm. For all studies, we used intention to treat analysis. In cases of 
discrepancy or doubt about the number of events (stroke/TIA), we contacted authors to clarify details. 
Outcomes were recorded separately for (i) stroke, excluding TIA, and, (ii) stroke including TIA with 
comparator arms classified as (i) placebo, B-vitamins and/or folic acid [where folic acid in the 
comparator arm was low-dose compared to the intervention arm], and (ii) placebo only, excluding 
studies in which no placebo or usual care was used (i.e. Wrone6  and Toole7), or events in participants 
randomised to vitamin B6 as one of three arms (i.e. Ebbing8 and Bonaa9). To increase comparability 
of RCTs with genetic studies, we selected only stroke events excluding TIA as the main outcome and 
compared intervention with any of placebo, vitamin B and/or (low-dose) folic acid. 
 
Genetic studies 
For genetic studies the following variables were extracted (by PN and MVH, see eTable 1 and 2): 
study design, participant characteristics, country and calendar year in which the study was conducted, 
study design, proportion of males, mean age of participants, frequency of genotypes and alleles by 
case control status, average value (mean, median) and measure of dispersion (standard deviation, 
standard error, confidence interval, inter-quartile range or range) of Hcy and folic acid concentrations, 
stroke sub-type(s), language of publication, and ethnic background. We also calculated Hardy-
Weinberg equilibriums (HWE) and disequilibrium coefficients for all genetic studies: in studies of 
MTHFR-stroke, only allele frequencies in controls were used; in MTHFR-homocysteine studies, allele 
frequencies of all participants were used. Where the number of subjects per genotype was 
selected/restricted a priori by the study investigators, HWE values were not estimated. For plots of 
allele frequency, we categorized studies into (i) probable folate status category, and (ii) ethnicity. 
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Ethnicity was classified according to the subjects investigated: studies or study subsets were 
categorized as follows: (i) Caucasian: including Israel and Turkey; (ii) African; (iii) East Asia including 
individuals from Japan, China, Korea, Hong Kong and Mongolia; (iv) South Asia including India, 
Pakistan and Bangladesh; (v) Latin America, and; (vii) mixed ethnicity. Plots were restricted to those 
studies that had values for all 3 genotypes and/or had not selected the number of subjects per 
genotype status.  
 
Categorization of genetic studies by probable folate status 
These categories (developed and validated by Dr Robert Clarke, Clinical Trial Service Unit (CTSU) 
and Epidemiological Studies Unit, University of Oxford, UK) used information on geographical location 
and dates during which the genetic study was conducted. and considered: (i) whether policies for folic 
acid fortification had been initiated and the date of implementation, and; (ii) whether there had been a 
change in folic acid levels at population levels though time. This information was derived from 
population based studies with information on folic acid. Geographical regions served as proxies of 
folate supplementation status. Categories were sorted according to the level of folic supplementation 
from the lowest to the highest as follows. (1) Asia: in addition to Asian countries (e.g. China, India, 
Hong Kong, Korea, Thailand, Mongolia) this category also included countries from North and sub-
Saharan Africa conducted at any time. (2) Europe-low (pre-fortification): including studies from 
Ireland, Scandinavia (Denmark, Norway, Sweden, Finland), Netherlands, Russia and Turkey 
conducted at any time, and European countries conducted prior to folic acid fortification of cereal and 
flour, initiated in 1996. (3) Europe mid (post-fortification): including all European countries in 1996 or 
thereafter (except Ireland, Scandinavia, Netherlands, Russia or Turkey). (4) America & Australia & 
New Zealand mid (pre-fortification): which included studies from North-America, Australia and New 
Zealand prior to 1996, and studies from Central and South America conducted at any time, except for 
Chile, in which only studies conducted prior to 2000 were classified in this category. (5) America & 
Australia & New Zealand high (post-fortification): which included studies from North-America, 
Australia and New Zealand conducted in 1996 and thereafter, and studies conducted in Chile in 2000 
and thereafter. For 67 studies (of 137) on which information was unavailable (from the publication, or 
previous publications from the same study, or after contacting study authors) on the timing of the 
study, 2-years prior to the publication date was used as the year the study was conducted. This value 
(median) was derived from the 70 studies that provided information on time of study conducted and 
year of publication Information on the categories allocated to each genetic dataset included in the 




All meta analyses were performed using the ‘metan’ command10  in Stata (StataCorp, Texas, USA) 
version 11.1. For meta-analysis of genetic association studies, we followed guidance from the Human 
Genome Epidemiology Network (HuGENet) HuGE Review Handbook11.  
 
3
MTHFR and homocysteine level  
The estimate of the mean difference was restricted to individuals without clinical evidence of 
cardiovascular disease (ischaemic heart disease, stroke, or venous thrombosis). In order to explore 
the modifying effect of folic acid levels on the MTHFR/C677T-Hcy association, two strategies were 
utilized. First, we conducted a stratified meta analysis of the effect of the MTHFR/C677T variant on 
Hcy levels according to the ‘probable folate categories’. Second, we performed a meta-regression 
analysis of the difference in Hcy levels by genotype against the average concentration of folic acid in 
each study. Analyses were then repeated only in studies with sample size ≥500 individuals in order to 
explore the influence of small-study bias in addition to funnel plot and Egger regression tests12. 
 
MTHFR and Stroke 
The outcome ‘main stroke comparison’ was used to make comparisons with results from RCTs of Hcy 
lowering therapies. The ‘main stroke comparison’ included studies reporting: (i) only-ischaemic stroke, 
(ii) only-haemorrhagic stroke, (iii) both (ischaemic and haemorrhagic separately) stroke, or (iv) only 
unclassified stroke (studies in which neuroimaging tools were not available to classify the event as 
haemorrhagic or ischaemic). For studies reporting ischaemic and/or haemorrhagic stroke, diagnosis 
was by neuroimaging (MRI or CT). For this meta-analysis, we assumed equivalence between risk 
ratio and OR. We used the probable folate status categories to explore whether the MTHFR/C677T 
effect on stroke was modified by folic acid levels in a meta-regression. For studies with information on 
Hcy levels and stroke, the effect of the MTHR/C677T variant on stroke was stratified according to the 
difference in Hcy levels (in tertiles) determined by the genetic variant. 
 
Evaluation of small study bias 
To evaluate the potential influence of small-study bias on risk of stroke (MTHFR TT vs CC) in Asia, 
we first restricted the analysis to large studies with ≥400 stroke events. Second, we performed Egger 
regression tests12, which tests the null hypothesis that the funnel plot is symmetrical. Third, we 
implemented Duval and Tweedie’s ‘trim and fill’ method13 using the ‘metatrim’ command in Stata14. 
This method uses the observed asymmetry in the funnel plot to estimate the number and outcomes of 
missing studies, and adjusts the meta-analysis to incorporate missing data. Fourth, we generated a 
hypothetical study with 400 cases distributed evenly to CC and TT genotype groups according to a TT 
frequency of 15% (derived from HapMap values obtained at dbSNP; 
www.ncbi.nlm.nih.gov/projects/SNP) for genotype frequencies in Asian populations). We sequentially 
added the hypothetical studies and the used cumulative meta-analysis to estimate the number of such 
studies that would have to exist to:  
(a) reduce the point estimate to 1.15; the threshold at which evidence for a genetic association is 
downgraded based on the Venice criteria15; 
(b) reduce the point estimate to 1.10 (comparable to an expected relative risk reduction of 10% in an 
RCT of a Hcy lowering intervention), a threshold below which the sample size of a trial of a Hcy-
lowering intervention on stroke risk might become too large to be considered practical; 
(c) reduce the lower bound of the 95%CI to 1.00.  
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Finally, we compared the number of large studies (≥400 stroke cases) from Asia (low-folate region) 
category with other geographical regions. 
 
Although Mendelian randomisation studies minimise confounding by environmental factors that may 
confound the blood marker-disease association, they can still suffer from confounding by linkage 
disequilibrium (LD). This is particularly relevant since in recent years, genome wide association 
studies have identified hits for established cardiovascular risk factors such as blood pressure, among 
those a variant (rs17367504) within the MTHFR gene16. In addition, since we included studies from 
different genetic ancestries, it might be possible that a different set of correlations (LD) of the 
rs1801133 variant occurs amongst different ethnic groups (e.g. Asians vs. Europeans), which 
therefore could confound our analyses. To explore this, we used the GLIDERS software17 to evaluate 
long range LD for the rs1801133 variant among the main ethnic groups and cross-checked this 
information with genome wide association studies repositories (see Bioinformatics Tools below).  
 
Randomised clinical trials  
The trial arm containing Hcy-lowering treatment was assigned as the experimental group and 
compared against placebo, usual care, vitamin-B6 and/or low-dose folic acid. For the stroke outcome, 
we estimated log relative risk and log upper and log lower 95%CI and pooled estimates across 
studies using random (DerSimonian & Laird) and fixed (Mantel and Haenszel) effects modelling. The 
mean difference in change of Hcy between randomised groups (Δ-experimental arm minus Δ-
comparator) was calculated. In a similar fashion to the genetic studies, we evaluated the potential 
effect of folate status intake on the results of the randomised trials. We conducted meta-regression 
analysis of the log of the relative risk of the trials against: (i) the probable folate status categories 
(using the same criteria as for genetic studies) and separately (ii) the mean difference in Hcy 
achieved by the intervention. Sensitivity analyses were conducted according to: (i) sample size (using 
1000 randomised participants as a cut-point to dichotomise studies); (ii) risk of bias (low vs. any/high, 
according to Cochrane guidance5; see eTable 5); (iii) the outcome recorded (stroke only vs. stroke 
plus transient ischaemic attack - we re-estimated the relative risk of stroke for stroke plus TIA in 
studies where TIA was reported separately as a clinical event  (HOPE-218, Righetti19 and Wrone6 and; 
(iv) according to the reference arm used (placebo only vs. [placebo or vitamin-B6 alone]). In addition, 
the meta-analysis estimate computed by omitting one study at a time was conducted to check that no 
individual trial had a major influence on the summary estimate (eFigure 7). We used the DerSimonian 
and Laird Q test in all meta-analyses to evaluate the degree of heterogeneity between studies, and 
the I2 measure20 to describe the proportion of total variation in study estimates due to heterogeneity. 
Funnel plot and Egger regression tests were conducted to evaluate the presence of small-study bias.  
 
Bioinformatics tools 
We used GLIDERS17 (http://mather.well.ox.ac.uk/GLIDERS) to check for potential confounding by 
long-range linkage disequilibrium (LD). GLIDERS is a web-based tool that allows users to check long-
range LD (>200kb) between SNPs. Using HapMap phase 3, the following criteria were used: Build 36, 
5
MAF≥0.05, cis- and trans-chromosome, r2≥0.3, no lower/upper range (i.e. associations between any 
pair-wise HapMap SNPs over any distance would be retrieved), and searching all ancestries (Asian, 
European, African) separately. We searched for SNPs in long-range LD with rs1801133 retrieved 
from GLIDERS using 2 genome wide association studies repositories for associations with CVD traits 
and/or outcomes: (1) NHGRI GWAS Catalog21 and (2) SNPnexus http://www.snp-nexus.org. Both 
were accessed on 30th April 2009. 
 


























































eFigure 1. Frequency histogram of sample size and number of stroke cases for MTHFR-homocysteine (left panel)  
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Only studies with data on all 3 genotypes are presented 

















 eFigure 2(a) and (b) Genotype frequency of MTHFR/C677T variant in studies used to determine  
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eFigure 3(a) and (b) Genotype frequency of MTHFR/C677T variant in studies utilised to estimate the effect on stroke, 







































































































































































































































































































































Studies  Ischaemic + hemorrhagic or 
Studies unclassified 
Studies only  Ischaemic or 
Studies only  Haemorrhagic or 
Studies  Ischaemic + hemorrhagic  or 




Silent brain infarct 
Main comparison 
(94 datasets, 17,909 cases) 
(20 datasets, 1,615 cases) 
(25 datasets, 6,972 cases) 
(1 datasets, 161cases) 
(101 datasets, 20,885 cases) 
1.42 (1.28, 1.57) 
1.30 (0.98, 1.72) 
1.11 (0.95, 1.29) 
1.66 (0.80, 3.46) 
1.37 (1.25, 1.50) 
  
1 0.8 1.4 2 
1.16 (1.09, 1.24) 
1.08 (0.88, 1.32) 
1.08 (0.96, 1.22) 
0.96 (0.56, 1.63) 
1.14 (1.08, 1.21) 
  
1 0.8 1.4 2   
  Lower risk             Higher risk Lower risk             Higher risk 
Stroke subtype Odds ratio (95% CI) 
MTHFR TT vs. CC  
Odds ratio (95% CI) 
MTHFR CT vs. CC 
eFigure 4  Odds ratio of the MTHFR/C677T variant on different stroke sub-types. Left panel compares 























eFigure 5  Contour-enhanced funnel plot of MTHFR-stroke studies in Asia using the trim and fill analysis. 
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ΔHcy 0.64 (-2.13 to 2.15) µmol/l 
ΔHcy 6.66 (3.26 to 19.73) µmol/l ΔHcy 1.82 (0.90 to 3.71) µmol/l 
ΔHcy 2.69 (2.16 to 3.22) µmol/l ΔHcy 0.46 (0.30 to 0.77) µmol/l 
    Lower risk                       High risk Lower risk                       High risk 
eFigure 6. Odds ratio of the MTHFR/C677T variant on stroke stratified according to the tertile of difference in homocysteine 
determined by the genetic variant. Left panel compares individuals homozygous for T-allele with CC subjects. Right panel 
compares heterozygous with CC subjects. 
15
Relative risk of stroke 
eFigure 7  Influence analysis to evaluate the effect of individual trials, omitted one at a time, on the summary estimate 




eTable 1. Characteristics of genetic studies included in the analysis of MTHFR/C677T and 
homocysteine levels. 
eTable 2. Characteristics of genetic studies included in the analysis of MTHFR/C677T and 
stroke risk.   
eTable 3. Sensitivity analysis to illustrate the number of hypothetical large null studies that 
are needed to shift the point estimate observed in the MTHFR/C677T-stroke meta-analysis 
to several thresholds. 
eTable 4. Linkage disequilibrium of the MTHFR/C677T variant by ethnic group. 































Nakata Y s057a 1992‐1995 NA Japan Asia East Asian NR NR 30 92 66 30.72 90.55 66.72 0.8800 ‐0.0038
Yoo JH‐2000 s029a 1996‐1997 NA Korea Asia East Asian 53 52 16 64 42 18.89 58.23 44.89 0.3440 ‐0.0236
Kohara K s062a 1997‐1999 NA Japan Asia East Asian 50 NR 305 956 744 305.78 954.44 744.78 0.9626 ‐0.0004
Li Z s058a 2000‐2001 NA China Asia East Asian 57 NR 398 824 610 358.13 903.73 570.13 0.0002 0.0218
Choi BO s059a 2000‐2002 NA Korea Asia East Asian 56 NR 25 100 73 28.41 93.18 76.41 0.3654 ‐0.0172
Kim OJ2 s068b 2000‐2002 NA Korea Asia East Asian 53 NR 38 119 66 42.63 109.74 70.63 0.2243 ‐0.0208
Kim NK s061a 2000‐2003 NA South Korea Asia East Asian 45 NR 16 71 39 21.05 60.90 44.05 0.0960 ‐0.0401
Biswas A s075a 2003‐2004 NA India Asia South Asian NR NR 4 26 46 3.80 26.39 45.80 1.0000 0.0026
Ou T s035 NR 1996 Japan Asia East Asian 86 55 27 19 39 15.67 41.65 27.67 0.0000 0.1333
Ho CH s008 NR 1998 China Asia East Asian 68 64 69 164 212 51.24 199.52 194.24 0.0002 0.0399
Vizcaino G s036 NR 1999 India Asia South Asian NR 30 14 50 27 16.71 44.57 29.71 0.2907 ‐0.0298
Somekawa Y s012 NR 2000 Japan Asia East Asian 0 55 30 91 96 26.27 98.46 92.27 0.2945 0.0172
Jee SH s032a NR 2000 Korea Asia East Asian 44 37 76 184 135 71.45 193.09 130.45 0.3550 0.0115
Yingdong Z s040a NR 2000 China Asia East Asian 48 59 5 16 21 4.02 17.95 20.02 0.4809 0.0232
Huang Y s060b NR 2000 China Asia East Asian NR NR 11 26 18 10.47 27.05 17.47 0.7870 0.0096
Miyaki K s069a NR 2002 Japan Asia East Asian 77 NR 10 24 17 9.49 25.02 16.49 0.7791 0.0100
Fang X s064a NR 2003 Mongolia Asia East Asian 54 NR 2 6 16 1.04 7.92 15.04 0.2324 0.0399
Kim IG s074a NR 2005 Korea Asia East Asian 45 NR 15 61 34 18.82 53.36 37.82 0.1705 ‐0.0347
Voutilainen S s010 1984‐1996 NA Finland Europe‐low Caucasian 100 54 11 57 100 9.29 60.43 98.29 0.5185 0.0102
Thogersen AM s002a 1986‐1994 NA Sweden Europe‐low Caucasian 79 55 7 51 71 8.19 48.62 72.19 0.8147 ‐0.0092
Meleady R s027a 1990‐1992 NA 9 European Countries Europe‐low Caucasian 72 44 81 314 352 75.83 324.34 346.83 0.3994 0.0069
Slooter AJ s071a 1990‐2001 NA Netherlands Europe‐low Caucasian 0 NR 59 274 292 61.47 269.07 294.47 0.7102 ‐0.0039
Frederiksen J s066b 1991‐2002 NA Denmark Europe‐low Caucasian 42 NR 315 1600 1804 334.29 1561.42 1823.29 0.1378 ‐0.0052
de Bree A. s034 1993‐1996 NA Netherlands Europe‐low Caucasian 53 41 206 907 983 207.51 903.98 984.51 0.9193 ‐0.0007
Cappuccio FP s018 1994‐1996 NA UK Europe‐low Mixed ethnicity 45 50 64 391 916 49.12 420.76 901.12 0.0105 0.0109
Husemoen LLN s023 1999‐2001 NA Finland Europe‐low Caucasian 48 46 246 1181 1361 250.98 1171.04 1365.98 0.6849 ‐0.0018
Hustad S s028 NR 1998 Norway Europe‐low Caucasian 62 41 37 182 204 38.73 178.53 205.73 0.7308 ‐0.0041
Silaste ML s014 NR 1999 Finland Europe‐low Caucasian 0 NR 5 13 19 3.57 15.85 17.57 0.2679 0.0385
Shmeleva V s073a NR 2003 Russia Europe‐low Caucasian NR NR 6 30 24 7.35 27.30 25.35 0.5746 ‐0.0225
Karakus Z s076a NR 2003 Turkey Europe‐low Caucasian 52 NR 7 36 37 7.81 34.38 37.81 0.7977 ‐0.0102
Dikmen M s063b NR 2004 Turkey Europe‐low Caucasian 29 NR 2 21 32 2.84 19.32 32.84 0.7110 ‐0.0153
D'Angelo A. s037a 1996 NA Italy Europe‐mid  Caucasian 52 41 39 98 45 42.55 90.90 48.55 0.3727 ‐0.0195
Dekou V. s009a 1996 NA England Europe‐mid  Caucasian 0 66 36 149 161 35.29 150.42 160.29 0.9016 0.0021
Dekou V. s009b 1996 NA England Europe‐mid  Caucasian 100 66 36 188 184 41.42 177.16 189.42 0.2543 ‐0.0133
Chango A s017 1997 NA France Europe‐mid  Caucasian 45 NR 49 125 117 42.72 137.55 110.72 0.1362 0.0216
Reyes‐Engel A s024 1998 NA Spain Europe‐mid  Caucasian 49 45 119 413 249 135.66 379.68 265.66 0.0153 ‐0.0213
NPHS_II s072b 1989‐ 2005 NA United Kingdom Europe‐mid  Caucasian 100 NR 150 579 631 142.03 594.94 623.03 0.3217 0.0059
Fowkes G s065b 1992‐2002 NA United Kingdom Europe‐mid  Caucasian NR NR 60 323 315 70.29 302.42 325.29 0.0807 ‐0.0147
Meisel C s007a 1995‐1997 NA Germany Europe‐mid  Caucasian 76 61 96 217 120 96.58 215.83 120.58 1.0000 ‐0.0013
Chambers JC s004c 1995‐1998 NA UK Europe‐mid  Caucasian 100 50 41 195 188 45.24 186.52 192.24 0.3787 ‐0.0100
Chambers JC s004a 1995‐1998 NA UK Europe‐mid  South Asian 100 49 12 90 279 8.53 96.94 275.53 0.1596 0.0091
Gemmati D s039a 1996‐1997 NA Italy Europe‐mid  Caucasian 61 47 39 116 65 42.77 108.46 68.77 0.3402 ‐0.0171
Pezzini A s070b 1997‐2000 NA Italy Europe‐mid  Caucasian 54 NR 20 60 50 19.23 61.54 49.23 0.8529 0.0059
Domagala TB s016a 1998‐2000 NA Poland Europe‐mid  Caucasian 72 45 6 37 57 6.00 36.99 57.00 1.0000 0.0000
HAPIEE study S176 2002‐2005 NA zech Republic, Poland, Russ Europe‐mid  Caucasian 47 NR 70 273 312 65.10 282.79 307.10 0.3667 0.0075
Thuillier L s011a NR 1996 France Europe‐mid  Caucasian 34 43 10 32 27 9.80 32.41 26.80 1.0000 0.0029
Zittoun J s038 NR 1996 France Europe‐mid  Caucasian 46 33 6 20 26 4.92 22.15 24.92 0.5179 0.0207
Friedman G s022 NR 1997 Israel Europe‐mid  Caucasian 50 57 55 172 150 52.73 176.53 147.73 0.6598 0.0060
Chango A s020 NR 1998 France Europe‐mid  Caucasian 45 NR 12 25 29 9.09 30.81 26.09 0.1220 0.0440
Passaro A s030 NR 1999 Italy Europe‐mid  Caucasian 0 62 20 72 28 26.13 59.73 34.13 0.0295 ‐0.0511
Pullin C s031 NR 1999 UK Europe‐mid  Caucasian 42 39 42 42 42 31.50 63.00 31.50 0.0002 0.0833
Litynski P s033 NR 2000 Switzerland Europe‐mid  Caucasian 80 NR 20 NR 20 NA NA NA NA NA
Fohr IP s005 NR 2000 Germany Europe‐mid  Caucasian 0 24 21 75 64 21.39 74.22 64.39 1.0000 ‐0.0024
Castro R s019 NR 2001 Portugal Europe‐mid  Caucasian 39 41 12 54 51 13.00 52.00 52.00 0.8353 ‐0.0085
Hassan A s067b NR 2002 United Kingdom Europe‐mid  Caucasian 58 NR 49 144 147 43.06 155.88 141.06 0.1573 0.0175
Linnebank M s078 NR 2004 Germany Europe‐mid  Caucasian NR NR 8 67 64 12.39 58.22 68.39 0.1045 ‐0.0316
Ma J s021a 1982 NA USA America‐ANZ mid Caucasian 100 60 39 116 193 27.04 139.93 181.04 0.0020 0.0344
Christensen B. s026a 1986‐1987 NA Canada America‐ANZ mid Caucasian 100 42 8 47 31 11.54 39.92 34.54 0.1615 ‐0.0411
Jacques PF s013 1991‐1994 NA USA America‐ANZ mid Caucasian 50 57 149 152 149 112.50 225.00 112.50 0.0000 0.0811
Schwartz SM s025 1991‐1995 NA USA America‐ANZ mid Caucasian 0 NR 43 141 154 38.11 150.77 149.11 0.2251 0.0145
Varela MI s041a 1997‐2000 NA Argentina America‐ANZ mid Latin American 56 40 22 73 49 23.77 69.47 50.77 0.6068 ‐0.0123
Schmitz C s003 1996 NA USA America‐ANZ high Caucasian NR 59 56 156 166 47.50 172.99 157.50 0.0566 0.0225
Guinotte ChL s006 1998 NA USA America‐ANZ high Caucasian 100 25 17 12 14 12.30 21.40 9.30 0.0052 0.1092
Caudill MA s001 1999 NA USA America‐ANZ high Caucasian 0 26 9 50 75 8.63 50.73 74.63 0.8221 0.0028
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Zee RY_WHS s077b 1992‐2000 NA USA America‐ANZ high Caucasian 0 NR 2773 10966 11229 2729.96 11052.09 11185.96 0.2189 0.0017
Eikelboom JW s056a 1996‐1998 NA Australia America‐ANZ high Caucasian 60 NR 23 98 84 25.29 93.42 86.29 0.5419 ‐0.0112






























Morita H s047a Ischaemic 1996‐1997 NA Japan Asia East Asian 54 33 139 153 32.33 140.35 152.33 0.8978 0.0021
Nakata Y s057d Ischaemic 1992‐1995 NA Japan Asia East Asian NR 19 51 35 18.86 51.28 34.86 1.0000 0.0013
Notsu Y s103 Ischaemic 1995‐1997 NA Japan Asia East Asian 58 31 92 86 28.37 97.26 83.37 0.4578 0.0126
Teng L s156 Ischaemic NR 1997 China Asia East Asian NR 10 43 26 12.56 37.88 28.56 0.3466 ‐0.0324
Yoo JH s095 Ischaemic 1998 NA Korea Asia East Asian 40 26 114 77 31.75 102.51 82.75 0.1152 ‐0.0265
Zheng YZ s096c Ischaemic NR 1998 China Asia East Asian 52 15 45 62 11.53 51.95 58.53 0.1400 0.0285
Wu Y s110 Ischaemic NR 1999 Japan Asia East Asian 52 24 113 92 28.30 104.40 96.30 0.2477 ‐0.0188
Kawamoto R s135 Ischaemic 1999‐2000 NA Japan Asia East Asian NR 28 78 80 24.13 85.73 76.13 0.2645 0.0208
Zhang YD s159 Ischaemic NR 1999 China Asia East Asian NR 5 16 21 4.02 17.95 20.02 0.4809 0.0232
Zhang G s094 Ischaemic 1999‐2000 NA China Asia East Asian 70 16 47 37 15.60 47.80 36.60 0.8370 0.0040
Li C s114 Ischaemic NR 2000 China Asia East Asian NR 8 49 97 6.86 51.28 95.86 0.6273 0.0074
Tu s157 Ischaemic NR 2000 China Asia East Asian NR 7 35 25 8.96 31.08 26.96 0.4299 ‐0.0292
Yingdong Z s040b Ischaemic NR 2000 China Asia East Asian 48 5 16 21 4.02 17.95 20.02 0.4809 0.0232
Huang Y s060a Ischaemic NR 2000 China Asia East Asian NR 11 26 18 10.47 27.05 17.47 0.7870 0.0096
Gao HF s152 Ischaemic NR 2001 China Asia East Asian NR 8 13 19 5.26 18.49 16.26 0.0837 0.0686
Sun WP s155 Ischaemic NR 2001 China Asia East Asian NR 15 46 25 16.79 42.42 26.79 0.5155 ‐0.0208
Zhang Y s160 Ischaemic NR 2001 China Asia East Asian NR 67 126 66 65.25 129.50 64.25 0.7092 0.0068
Li Z s058d Ischaemic 2000‐2001 NA China Asia East Asian 57 398 824 610 358.13 903.73 570.13 0.0002 0.0218
Choi BO s059b Ischaemic 2000‐2002 NA Korea Asia East Asian 56 25 100 73 28.41 93.18 76.41 0.3654 ‐0.0172
Kohara K s062b Ischaemic 1997‐1999 NA Japan Asia East Asian 50 290 940 727 295.15 929.71 732.15 0.6345 ‐0.0026
Ye H s131c Ischaemic NR 2002 China Asia East Asian NR 21 87 192 13.87 101.27 184.87 0.0167 0.0238
Baum L s132 Ischaemic 2002‐2003 NA Hong Kong Asia East Asian 71 14 95 195 12.44 98.12 193.44 0.5938 0.0051
Fang L s151b Ischaemic NR 2002 China Asia East Asian NR 19 37 40 14.65 45.70 35.65 0.0846 0.0453
NG KM s165 Ischaemic NR 2002 China Asia East Asian NR 1 33 49 3.69 27.62 51.69 0.1041 ‐0.0324
Miyaki K s069b Ischaemic NR 2002 Japan Asia East Asian 77 32 93 62 32.95 91.09 62.95 0.8807 ‐0.0051
Alluri RV s127c Ischaemic 2002‐2003 NA India Asia South Asian NR 0 1 48 0.01 0.99 48.01 1.0000 ‐0.0001
Li YJ s153 Ischaemic NR 2003 China Asia East Asian NR 24 44 32 21.16 49.68 29.16 0.3130 0.0284
Qin s154 Ischaemic NR 2003 China Asia East Asian NR 5 12 8 4.84 12.32 7.84 1.0000 0.0064
Fang X s064d Ischaemic NR 2003 Mongolia Asia East Asian 54 2 6 16 1.04 7.92 15.04 0.2324 0.0399
Yamada Y s148a Ischaemic 2002‐2005 NA Japan Asia East Asian 42 NR§ NR§ NR§ NA NA NA NA NA
Xiao YQ s158 Ischaemic NR 2004 China Asia East Asian NR 10 41 49 9.30 42.39 48.30 0.8133 0.0070
Li CM s163 Ischaemic NR 2004 China Asia East Asian NR 16 128 190 19.16 121.68 193.16 0.4518 ‐0.0095
Nan GX s164 Ischaemic 2003‐2004 NA China Asia East Asian 70 19 53 28 20.70 49.60 29.70 0.5503 ‐0.0170
XuGuang G s170 Ischaemic 2004 NA China Asia East Asian 71 24 44 32 21.16 49.68 29.16 0.3130 0.0284
Fang L s161a Ischaemic NR 2005 China Asia East Asian NR 24 40 52 16.69 54.62 44.69 0.0053 0.0630
Kim OJ s068d Ischaemic 2000‐2002 NA Korea Asia East Asian 53 38 119 66 42.63 109.74 70.63 0.2243 ‐0.0208
Kim IG s074b Ischaemic NR 2005 Korea Asia East Asian 45 15 61 34 18.82 53.36 37.82 0.1705 ‐0.0347
Moe KT s173 Ischaemic NR 2006 Singapore Asia East Asian 76 3 68 136 6.61 60.77 139.61 0.1016 ‐0.0175
Biswas A s075 Ischaemic 2003‐2004 NA India Asia South Asian NR 0 30 90 1.88 26.25 91.88 0.2108 ‐0.0156
Kim NK s061b Silent brain infarction 2000‐2003 NA South Korea Asia East Asian 45 16 71 39 21.05 60.90 44.05 0.0960 ‐0.0401
Nakata Y s057b Total stroke (isch+haem) 1992‐1995 NA Japan Asia East Asian NR 19 51 35 18.86 51.28 34.86 1.0000 0.0013
Zheng YZ s096a Total stroke (isch+haem) NR 1998 China Asia East Asian 52 15 45 62 11.53 51.95 58.53 0.1400 0.0285
Li Z s058b Total stroke (isch+haem) 2000‐2001 NA China Asia East Asian 57 398 824 610 358.13 903.73 570.13 0.0002 0.0218
Ye H s131a Total stroke (isch+haem) NR 2002 China Asia East Asian NR 21 87 192 13.87 101.27 184.87 0.0167 0.0238
Alluri RV s127a Total stroke (isch+haem) 2002‐2003 NA India Asia South Asian NR 0 1 48 0.01 0.99 48.01 1.0000 ‐0.0001
Fang X s064b Total stroke (isch+haem) NR 2003 Mongolia Asia East Asian 54 2 6 16 1.04 7.92 15.04 0.2324 0.0399
Kim OJ2 s068a Total stroke (isch+haem) 2000‐2002 NA Korea Asia East Asian 53 38 119 66 42.63 109.74 70.63 0.2243 ‐0.0208
Nakata Y s057c Haemorrhagic 1992‐1995 NA Japan Asia East Asian NR 19 51 35 18.86 51.28 34.86 1.0000 0.0013
Zheng YZ s096b Haemorrhagic NR 1998 China Asia East Asian 52 15 45 62 11.53 51.95 58.53 0.1400 0.0285
Li Z s058c Haemorrhagic 2000‐2001 NA China Asia East Asian 57 398 824 610 358.13 903.73 570.13 0.0002 0.0218
Ye H s131b Haemorrhagic NR 2002 China Asia East Asian NR 21 87 192 13.87 101.27 184.87 0.0167 0.0238
Alluri RV s127b Haemorrhagic 2002‐2003 NA India Asia South Asian NR 0 1 48 0.01 0.99 48.01 1.0000 ‐0.0001
Fang X s064c Haemorrhagic NR 2003 Mongolia Asia East Asian 54 2 6 16 1.04 7.92 15.04 0.2324 0.0399
Kim OJ2 s068c Haemorrhagic 2000‐2002 NA Korea Asia East Asian 53 38 119 66 42.63 109.74 70.63 0.2243 ‐0.0208
Somarajan s178a Total stroke (isch+haem) 2005‐2009 NA India Asia South Asian 72 5 54 129 5.45 53.11 129.45 1.0000 ‐0.0024
Somarajan s178b Ischaemic 2005‐2009 NA India Asia South Asian 73 5 54 129 5.45 53.11 129.45 1.0000 ‐0.0024
Somarajan s178c Haemorrhagic 2005‐2009 NA India Asia South Asian 70 5 54 129 5.45 53.11 129.45 1.0000 ‐0.0024
Duca F s115 Ischaemic NR 1995 Italy Europe‐low Caucasian NR 52 99 74 45.79 111.42 67.79 0.1059 0.0276
Markus HS s053a Ischaemic NR 1995 United Kingdom Europe‐low Caucasian 48 22 63 76 17.78 71.44 71.78 0.1545 0.0262
Kostulas K s098 Ischaemic NR 1996 Sweden Europe‐low Caucasian NR 13 50 63 11.46 53.08 61.46 0.5276 0.0122
Kristensen B s108 Ischaemic 1991‐1996 NA Sweden Europe‐low Caucasian 49 3 14 24 2.44 15.12 23.44 0.6736 0.0137
Roest M s140c Ischaemic 1976‐1995 NA Netherlands Europe‐low Caucasian 0 NR§ NR§ NR§ NA NA NA NA NA
Kalashnikova L s119 Ischaemic NR 2001 Russia Europe‐low Caucasian NR 2 11 17 1.88 11.25 16.88 1.0000 0.0042
Ucar F s168 Ischaemic NR 2002 Turkey Europe‐low Caucasian 87 8 111 123 16.66 93.68 131.66 0.0044 ‐0.0358
Frederiksen J s066c Ischaemic 1991‐2002 NA Denmark Europe‐low Caucasian 42 315 1600 1804 334.29 1561.42 1823.29 0.1378 ‐0.0052
Frederiksen J s066e Ischaemic 1994‐2002 NA Denmark Europe‐low Caucasian 42 680 3213 3614 696.43 3180.14 3630.43 0.3833 ‐0.0022
Slooter AJ s071b Ischaemic 1990‐2001 NA Netherlands Europe‐low Caucasian 0 69 328 367 71.06 323.88 369.06 0.7979 ‐0.0027
Shmeleva V s073b Ischaemic NR 2003 Russia Europe‐low Caucasian NR 23 90 114 20.37 95.26 111.37 0.4291 0.0116
Karakus Z s076b Ischaemic NR 2003 Turkey Europe‐low Caucasian 52 7 36 37 7.81 34.38 37.81 0.7977 ‐0.0102
Dikmen M s063d Ischaemic NR 2004 Turkey Europe‐low Caucasian 29 2 21 32 2.84 19.32 32.84 0.7110 ‐0.0153
Kostulas K s149 Ischaemic NR 2006 Sweden Europe‐low Caucasian NR 56 206 249 49.47 219.05 242.47 0.1803 0.0128
Rotterdam Study s174c Ischaemic 1990+ NA Netherlands Europe‐low Caucasian NR 631 2774 2807 655.56 2724.88 2831.56 0.1650 ‐0.0040
Roest M s140a Total stroke (isch+haem) 1976‐1995 NA Netherlands Europe‐low Caucasian 0 NR§ NR§ NR§ NA NA NA NA NA
Frederiksen J s066a Total stroke (isch+haem) 1991‐2002 NA Denmark Europe‐low Caucasian 42 315 1600 1804 334.29 1561.42 1823.29 0.1378 ‐0.0052
Dikmen M s063a Total stroke (isch+haem) NR 2004 Turkey Europe‐low Caucasian 29 2 21 32 2.84 19.32 32.84 0.7110 ‐0.0153
Rotterdam Study s174a Total stroke (isch+haem) 1990+ NA Netherlands Europe‐low Caucasian NR 631 2774 2807 655.56 2724.88 2831.56 0.1650 ‐0.0040
Roest M s140b Haemorrhagic 1976‐1995 NA Netherlands Europe‐low Caucasian 0 NR§ NR§ NR§ NA NA NA NA NA
Frederiksen J s066d Haemorrhagic 1991‐2002 NA Denmark Europe‐low Caucasian 42 315 1600 1804 334.29 1561.42 1823.29 0.1378 ‐0.0052
Dikmen M s063c Haemorrhagic NR 2004 Turkey Europe‐low Caucasian 29 2 21 32 2.84 19.32 32.84 0.7110 ‐0.0153
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Rotterdam Study s174b Haemorrhagic 1990+ NA Netherlands Europe‐low Caucasian NR 631 2774 2807 655.56 2724.88 2831.56 0.1650 ‐0.0040
De Stefano V s101 Ischaemic 1994‐1997 NA Italy Europe‐mid  Caucasian 39 35 98 65 35.64 96.73 65.64 0.8854 ‐0.0032
Reuner KH s093 Ischaemic NR 1996 Germany Europe‐mid  Caucasian NR 23 74 85 19.78 80.44 81.78 0.3137 0.0177
Salooja N s097 Ischaemic NR 1996 United Kingdom Europe‐mid  Caucasian 53 16 76 81 16.86 74.29 81.86 0.8602 ‐0.0049
Lalouschek W s100 Ischaemic NR 1997 Austria Europe‐mid  Caucasian 60 10 47 39 11.69 43.62 40.69 0.5084 ‐0.0176
Margaglione M s105 Ischaemic 1996‐1998 NA Italy Europe‐mid  Caucasian 43 196 513 327 197.64 509.72 328.64 0.8500 ‐0.0016
Harmon DL s107 Ischaemic 1996‐1997 NA Ireland Europe‐mid  Caucasian 25 19 78 86 18.38 79.23 85.38 0.8646 0.0034
Gross B s116 Ischaemic NR 1998 Israel Europe‐mid  Caucasian NR 15 50 47 14.29 51.43 46.29 0.8369 0.0064
Topic E s112 Ischaemic NR 1999 Croatia Europe‐mid  Caucasian NR 1 59 64 7.50 46.00 70.50 0.0012 ‐0.0524
De Stefano V s117 Ischaemic NR 1999 Italy Europe‐mid  Caucasian 53 80 197 205 66.10 224.79 191.10 0.0082 0.0288
Lopaciuk S s099 Ischaemic 1996‐1999 NA Poland Europe‐mid  Caucasian 66 26 95 117 22.70 101.60 113.70 0.3614 0.0139
Pezzini A s109 Ischaemic 1997‐2000 NA Italy Europe‐mid  Caucasian 64 4 14 18 3.36 15.28 17.36 0.6952 0.0177
Pongracz E s113c Ischaemic NR 2000 Hungary Europe‐mid  Caucasian NR 7 46 120 5.20 49.60 118.20 0.2998 0.0104
McIlroy SP s162 Ischaemic NR 2000 Ireland Europe‐mid  Caucasian 20 2 19 50 1.86 19.27 49.86 1.0000 0.0019
Grossmann R s092 Ischaemic 1997‐2000 NA Germany Europe‐mid  Caucasian 49 26 91 69 27.49 88.03 70.49 0.7567 ‐0.0080
Szolnoki Z s102 Ischaemic 1998‐2002 NA Hungary Europe‐mid  Caucasian 53 89 268 386 66.93 312.14 363.93 0.0002 0.0297
Pezzini A s106 Ischaemic 1997‐2000 NA Italy Europe‐mid  Caucasian 54 23 72 54 23.36 71.28 54.36 1.0000 ‐0.0024
Pratnicka M s118d Ischaemic NR 2001 Poland Europe‐mid  Caucasian NR 8 54 88 8.17 53.67 88.17 1.0000 ‐0.0011
Hassan A s067a Ischaemic NR 2002 United Kingdom Europe‐mid  Caucasian 58 16 73 81 16.21 72.57 81.21 1.0000 ‐0.0013
Linnebank M s137 Ischaemic 1999‐2001 NA Germany Europe‐mid  Caucasian 50 19 62 78 15.72 68.55 74.72 0.2685 0.0206
Pezzini A s138 Ischaemic 1997‐2002 NA Italy Europe‐mid  Caucasian 54 23 75 60 23.17 74.67 60.17 1.0000 ‐0.0005
Szolnoki Z s143 Ischaemic 1998‐2003 NA Hungary Europe‐mid  Caucasian 53 23 106 166 19.58 112.84 162.58 0.2892 0.0116
ye H s079 Ischaemic 1999‐2003 NA Italy Europe‐mid  Caucasian 67 97 286 232 93.66 292.68 228.66 0.6111 0.0054
Bosco P s128 Ischaemic NR 2004 Italy Europe‐mid  Caucasian 60 19 67 35 22.78 59.44 38.78 0.1977 ‐0.0312
Sazci A s142c Ischaemic 2001‐2003 NA Turkey Europe‐mid  Caucasian 56 25 119 115 27.57 113.86 117.57 0.5715 ‐0.0099
Szolnoki Z s144 Ischaemic 1998‐2003 NA Hungary Europe‐mid  Caucasian NR 10 32 60 6.63 38.75 56.63 0.1135 0.0331
Sanchez Marin J s171c Ischaemic 1998‐2001 NA Spain Europe‐mid  Caucasian 57 14 43 33 14.00 42.99 33.00 1.0000 0.0000
Pezzini A s070a Ischaemic 1997‐2000 NA Italy Europe‐mid  Caucasian 54 22 73 60 22.08 72.84 60.08 1.0000 ‐0.0005
Lalouschek W s136 Ischaemic 1998‐2001 NA Austria Europe‐mid  Caucasian 52 90 366 361 91.22 363.55 362.22 0.8753 ‐0.0015
Pezzini A s139 Ischaemic 1997‐2000 NA Italy Europe‐mid  Caucasian 0 22 110 84 27.45 99.10 89.45 0.1377 ‐0.0252
NPHS_II s072d Ischaemic 1989‐ 2003 NA United Kingdom Europe‐mid  Caucasian 100 251 1128 1241 253.52 1122.96 1243.52 0.8553 ‐0.0010
Salooja N s097a Total stroke (isch+haem) NR 1996 United Kingdom Europe‐mid  Caucasian 53 16 76 81 16.86 74.29 81.86 0.8602 ‐0.0049
Fowkes G s065a Total stroke (isch+haem) 1992‐2002 NA United Kingdom Europe‐mid  Caucasian 48 73 398 405 84.46 375.09 416.46 0.0824 ‐0.0131
Pongracz E s113a Total stroke (isch+haem) NR 2000 Hungary Europe‐mid  Caucasian NR 7 46 120 5.20 49.60 118.20 0.2998 0.0104
Hermans MP s129 Total stroke (isch+haem) NR 2003 Belgium Europe‐mid  Caucasian 58 22 58 62 18.32 65.37 58.32 0.2015 0.0259
Guiterrez JI s134 Total stroke (isch+haem) NR 2003 Spain Europe‐mid  Caucasian 49 24 79 56 25.36 76.28 57.36 0.7417 ‐0.0086
Sazci A s142a Total stroke (isch+haem) 2001‐2003 NA Turkey Europe‐mid  Caucasian 56 25 119 115 27.57 113.86 117.57 0.5715 ‐0.0099
Sanchez Marin J s171a Total stroke (isch+haem) 1998‐2001 NA Spain Europe‐mid  Caucasian 57 14 43 33 14.00 42.99 33.00 1.0000 0.0000
British Women Heart & Health s130 Total stroke (isch+haem) 1999‐2007 NA United Kingdom Europe‐mid  Caucasian 0 400 1515 1553 386.33 1542.33 1539.33 0.3026 0.0039
NPHS II s072a Total stroke (isch+haem) 1989‐ 2003 NA United Kingdom Europe‐mid  Caucasian 100 251 1128 1241 253.52 1122.96 1243.52 0.8553 ‐0.0010
EPIC Norfolk s175 Total stroke (isch+haem) 1997+ NA United Kingdom Europe‐mid  Caucasian NR 1982 7964 7956 1986.89 7954.22 7960.89 0.8797 ‐0.0003
Weikert C s177 Total stroke (isch+haem) 1994‐2004 NA Germany Europe‐mid  Caucasian 45 92 421 455 94.53 415.94 457.53 0.7648 ‐0.0026
Salooja N s097b Haemorrhagic NR 1996 United Kingdom Europe‐mid  Caucasian 53 16 76 81 16.86 74.29 81.86 0.8602 ‐0.0049
Pongracz E s113b Haemorrhagic NR 2000 Hungary Europe‐mid  Caucasian NR 7 46 120 5.20 49.60 118.20 0.2998 0.0104
Sanchez Marin J s142b Haemorrhagic 1998‐2001 NA Spain Europe‐mid  Caucasian 57 14 43 33 14.00 42.99 33.00 1.0000 0.0000
Sazci A s171b Haemorrhagic 2001‐2003 NA Turkey Europe‐mid  Caucasian 56 25 119 115 27.57 113.86 117.57 0.5715 ‐0.0099
NPHS II s072c Haemorrhagic 1989‐ 2003 NA United Kingdom Europe‐mid  Caucasian 100 251 1128 1241 253.52 1122.96 1243.52 0.8553 ‐0.0010
Linnebank M s169 Haemorrhagic 1999‐2001 NA Germany Europe‐mid  Caucasian NR 36 152 158 36.25 151.49 158.25 1.0000 ‐0.0007
Voetsch B s104a Ischaemic 1996‐1998 NA Brazil America‐ANZ mid Latin American 44 2 43 61 5.21 36.58 64.21 0.0936 ‐0.0303  
Voetsch B s104b Ischaemic 1996‐1998 NA Brazil America‐ANZ mid Latin American 44 14 57 48 15.18 54.64 49.18 0.6944 ‐0.0099
Voetsch B s146 Ischaemic 1996‐2000 NA Brazil America‐ANZ mid Mixed 46 11 66 41 16.41 55.19 46.41 0.0484 ‐0.0458
Shinjo SK s172 Ischaemic 1994‐2004 NA Brazil America‐ANZ mid Latin American 57 12 60 54 14.00 56.00 56.00 0.5476 ‐0.0159
Press RD s111 Ischaemic NR 1997 USA America‐ANZ high Caucasian 58 1 23 28 3.00 18.99 30.00 0.2505 ‐0.0386
Eikelboom JW s056d Ischaemic 1996‐1998 NA Australia America‐ANZ high Caucasian 60 23 98 84 25.29 93.42 86.29 0.5419 ‐0.0112
Zee RL s077a Ischaemic 1992‐2000 NA USA America‐ANZ high Caucasian 0 2773 10966 11229 2729.96 11052.09 11185.96 0.2189 0.0017
Eikelboom JW s056b Total stroke (isch+haem) 1996‐1998 NA Australia America‐ANZ high Caucasian 60 23 98 84 25.29 93.42 86.29 0.5419 ‐0.0112
Eikelboom JW s056c Haemorrhagic 1996‐1998 NA Australia America‐ANZ high Caucasian 60 23 98 84 25.29 93.42 86.29 0.5419 ‐0.0112














Observed result meta‐analysis 0 1.68 (1.44, 1.97) 0 1.28 (1.11, 1.48)
Reduce point  estimate to 1.15 41 1.15 (1.07, 1.23) 6 1.14 (1.03, 1.27)
Reduce point estimate to 1.10 60 1.10 (1.04, 1.16) 12 1.10 (1.00, 1.20)









Ancestry SNP Chromosome Position r2 with
rs number number (base pair) rs1801133 SNPnexus† GWAS catalog‡
Asian 9651118 1 11784801 0.38 none none
7554327 1 11784801 0.31 none none
2336377 1 11872557 0.3 none none
2639453 1 11905131 0.33 none none
European 6540999 1 11755953 0.32 none none
11121828 1 11757041 0.32 none none
7538516 1 11759269 0.32 none none
6697244 1 11761435 0.32 none none
4845882 1 11765754 0.34 none none
1994798 1 11777342 0.35 none none
6541003 1 11778454 0.36 none none
4846052 1 11780538 0.37 none none
4846054 1 11791817 0.34 none none
12404124 1 11796456 0.37 none none
198391 1 11799004 0.37 none none
198393 1 11802272 0.37 none none
198401 1 11810971 0.38 none none
535107 1 11812055 0.37 none none
198406 1 11820179 0.37 none none
Africa 4846052 1 11780538 0.56 none none
198401 1 11810971 0.62 none none
































Righetti (45) 2001‐2005 Chronic kidney disease Fatal and nonfatal stroke and TIA Italy 37 1 3 51 2 8 29 64 ‡ 5 0.25 125 Placebo low‐risk low‐risk unclear low‐risk low‐risk
House (49) 2001‐2007 Type 1 or 2 diabetes and diabetic 
nephropathy
Stroke (fatal and non‐fatal) β Canada  128 6 NA 124 1 NA 32 60.4 2.5 1 25 Placebo low‐risk low‐risk low‐risk low‐risk low‐risk
Liem (42) 1998‐2002 Stable CHD Fatal stroke, non‐fatal stroke and TIA                                                   Netherlands 300 8* NA 293 12* NA 42 65 ‡Ω 0.5 0 0 Usual care low‐risk unclear high‐risk low‐risk low‐risk
Zoungas (50) 1998‐2003 Chronic kidney disease Fatal and nonfatal stroke       Australia, New Zealand 156 8 NA 159 18 NA 43 56 ‡ 15 0 0 Placebo unclear unclear low‐risk low‐risk low‐risk
Wrone (51) 1998‐2000 Chronic kidney disease Stroke (unspecified) and TIA USA 351  19 6 177 8 1 24 60 ‡ 5 or 15 0.006 12.5 1 mg/d folic acid low‐risk low‐risk low‐risk low‐risk low‐risk
Jamison (52) 2001‐2003 Chronic kidney disease Fatal and nonfatal thromboembolic stroke USA 1032 37 NA 1024 41 NA 38 66 113 (5.5) 40 2 100 Placebo low‐risk unclear low‐risk low‐risk low‐risk
Ebbing (43) 1999‐2006 Stable angina, ACS or aortic valve 
stenosis
Nonfatal thromboembolic stroke and fatal stroke                 Norway 1544 28 NA 1552 39 NA 38 61 2557 (82.6) 0.8 0.4 40 Placebo / B6 low‐risk low‐risk low‐risk low‐risk high‐risk
Bonaa (44) 1998‐2002 Myocardial infarction  Any fatal and nonfatal stroke (including SAH)                                     Norway 1872 49 NA 1877 49 NA 36 63 3027 (80.7) 0.8 0.4 40 Placebo / B6 low‐risk low‐risk low‐risk low‐risk low‐risk
Albert (53) 1998‐2005 CVD or 3 risk factors for CVD Fatal and nonfatal stroke (ischaemic, haemorrhagic)                   USA 2721 79 NA 2721 69 NA 87 64 600 (11) 2.5 1 50 Placebo unclear unclear low‐risk low‐risk low‐risk
HOPE‐2 (48) 2000‐2005 CVD or diabetes Fatal and nonfatal stroke (ischaemic, haemorrhagic) and TIA   Canada, USA (72.1 %); Brazil, Western 
Europe, Slovakia (27.9 %) 2758 111 131 2764 147 120 60 69 1064 (19.3) 2.5 1 50 Placebo low‐risk low‐risk low‐risk low‐risk low‐risk
Toole (54) 1996‐2003 Ischaemic Stroke Recurrent ischaemic stroke (fatal & non‐fatal)                                   USA, Canada, Scotland 1827 152 NA 1853 148 NA 24 66 ‡ 2.5 0.4 25 20 micro g/d folic 
acid †
low‐risk low‐risk low‐risk low‐risk low‐risk  
SEARCH (46) 1998‐2005 Myocardial infarction  Any fatal and nonfatal stroke (including SAH)                                     United Kingdom 6033 269 NA 6031 265 NA 80 64 § (10) 2 1 0 Placebo low‐risk low‐risk low‐risk low‐risk low‐risk
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